Evidence map›Paper›PMID 30696947›Full record

ArticleLeukemia2019

A germline HLTF mutation in familial MDS induces DNA damage accumulation through impaired PCNA polyubiquitination.

Kensuke Takaoka, Masahito Kawazu, Junji Koya, Akihide Yoshimi, Yosuke Masamoto, Hiroaki Maki, Takashi Toya, Takashi Kobayashi, Yasuhito Nannya, Shunya Arai and 8 more

Abstract read
PubMed Publisher
In one paragraph

Article in Leukemia, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.6field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 12 citations in OpenAlex.

  1. Multi-omics analysis of HLTF context-dependent regulation across TCGA cohorts revealed its potential as new biomarker in tumour.Mammalian genome : official journal of the International Mammalian Genome Society · 2026
    Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Review
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 7 institutions in 1 country.

Kensuke TakaokaDepartment of Hematology and Oncology, The University of Tokyo, Tokyo, Japan.
Masahito KawazuDepartment of Medical Genomics, The University of Tokyo, Tokyo, Japan.
Junji KoyaDepartment of Hematology and Oncology, The University of Tokyo, Tokyo, Japan.
Akihide YoshimiDepartment of Hematology and Oncology, The University of Tokyo, Tokyo, Japan.ORCID http://orcid.org/0000-0002-0664-7281
Yosuke MasamotoDepartment of Hematology and Oncology, The University of Tokyo, Tokyo, Japan.
Hiroaki MakiDepartment of Hematology and Oncology, The University of Tokyo, Tokyo, Japan.
Takashi ToyaDepartment of Hematology and Oncology, The University of Tokyo, Tokyo, Japan.
Takashi KobayashiDepartment of Hematology and Oncology, The University of Tokyo, Tokyo, Japan.
Yasuhito NannyaDepartment of Hematology and Oncology, The University of Tokyo, Tokyo, Japan.
Shunya AraiDepartment of Hematology and Oncology, The University of Tokyo, Tokyo, Japan.ORCID http://orcid.org/0000-0003-0445-7991
Toshihide UenoDepartment of Cellular Signaling, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
Hironori UenoDepartment of Hematology, Tokyo Medical Center, Tokyo, Japan.
Kenshi SuzukiDepartment of Hematology, Japanese Red Cross Medical Center, Tokyo, Japan.
Hironori HaradaSchool of Life Sciences, Tokyo University of Pharmacy and Life Sciences, Tokyo, Japan.
Atsushi ManabeDepartment of Pediatrics, St. Luke's International Hospital, Tokyo, Japan.ORCID http://orcid.org/0000-0002-6698-2348
Yasuhide HayashiDepartment of Hematology/Oncology, Gunma Children's Medical Center, Gunma, Japan.
Hiroyuki ManoDepartment of Cellular Signaling, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
Mineo KurokawaDepartment of Hematology and Oncology, The University of Tokyo, Tokyo, Japan. kurokawa-tky@umin.ac.jp.
The University of Tokyo · JPGunma Children's Medical Center · JPJapanese Red Cross Medical Center · JPSt. Luke's International Hospital · JPTokyo Medical Center · JPTokyo Medical University · JPTokyo University of Pharmacy and Life Sciences · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Although several causal genes of familial myelodysplastic syndromes (MDS) have been identified, the genetic landscape and the molecular pathogenesis are not totally understood. To explore novel driver genes and their pathogenetic significance, we performed whole-exome sequence analysis of four individuals from a familial MDS pedigree and 10 candidate single-nucleotide variants (C9orf43, CYP7B1, EFHB, ENTPD7, FAM160B2, HELZ2, HLTF, INPP5J, ITPKB, and RYK) were identified. Knockdown screening revealed that Hltf downregulation enhanced colony-forming capacity of primary murine bone marrow (BM) stem/progenitor cells. γH2AX immunofluorescent staining assay revealed increased DNA damage in a human acute myeloid leukemia (AML) cell line ectopically expressing HLTF E259K, which was not observed in cells expressing wild-type HLTF. Silencing of HLTF in human AML cells also led to DNA damage, indicating that HLTF E259K is a loss-of-function mutation. Molecularly, we found that an E259K mutation reduced the binding capacity of HLTF with ubiquitin-conjugating enzymes, methanesulfonate sensitive 2 and ubiquitin-conjugating enzyme E2N, resulting in impaired polyubiquitination of proliferating cell nuclear antigen (PCNA) in HLTF E259K-transduced cells. In summary, our results indicate that a familial MDS-associated HLTF E259K germline mutation induces accumulation of DNA double-strand breaks, possibly through impaired PCNA polyubiquitination.

Indexed as

DNA DamageGerm-Line MutationUbiquitinationAgedAged, 80 and overBiomarkers, TumorDNA-Binding ProteinsDNA RepairFemaleGenetic Predisposition to DiseaseHumansMaleMiddle AgedMyelodysplastic SyndromesPedigreePolyubiquitinBiomarkers, TumorDNA-Binding ProteinsHLTF protein, humanPCNA protein, humanPolyubiquitinProliferating Cell Nuclear AntigenTranscription Factors

Identifiers

PMID30696947
OpenAlexW2914330621

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.